



AI in CVS Health: Navigating Risks & Unlocking Value

**PRESENTED BY: TEAM 17** 

February 19, 2025

Daryn Imashev, Gillis Wang, Isabella Chen, Nikita Suryawanshi, Jackson Sui



#### **Most impactful AI considerations**

-Data Privacy & Cybersecurity

-Bias in Al Models

-Al-Driven Drug Discovery & Clinical Insights

Mitigation & The Value of Each Approach

**Conclusion** 



## Data Privacy & Cybersecurity

CVS Health has already experienced cybersecurity incidents in 2021, highlighting the need for robust security measures.

#### **Privacy Concerns**

## In 2025, CVS Health's redesigned Alpowered app sparkles privacy concerns

over **sensitive health data handling.** 

 Using AI to create more intuitive workflows and faster turnaround times, which involves processing large amounts of patient and member data.

### **Cybersecurity Risks**

Learn from the past...

- The database leak exposed over 1 billion personal information, causing serious reputation damage and customer trust issue.
- The increasing reliance on AI may create new attack vectors for cybercriminals.

## Bias in Al models

## Al-driven Insurance & Claims Processing

- Aetna's Al may deny claims unfairly if trained on biased historical data, worsening healthcare disparities.
- In 2019, UnitedHealthcare's
   Al prioritized healthier
   patients, reducing care for
   Black patients with higher
   risks.

## Pharmacy AI & Prescription Approvals

- Al may reinforce racial and gender disparities in medication access if trained on biased data.
- In 2021, AI monitoring disproportionately flagged
   Black patients as "highrisk" opioid users, limiting pain treatment.

# & Wellness Recommendations

- Al may unequally distribute preventive care recommendations, favoring certain groups.
- prioritized white
  patients over Black
  patients for healthcare
  recommendations.

## Al-Driven Drug Discovery and Clinical Insights

Regulatory & Compliance Risks

**High Implementation Costs** 

Disruption to Traditional
Pharmacy & Provider Roles

- Models must adhere to strict FDA and healthcare regulations, which may delay implementation.
- IBM Watson faced scrutiny
   when it was revealed that the AI
   system provided
   incorrect/unsafe treatment
   recommendations.
- Deploying AI in drug discovery and medical practices requires investment in technology, personnel and infrastructure.
- BenevolentAI, a biotech company using AI for drug discovery, faced major financial difficulties despite initial successes.

- Automation may change the role of pharmacists and healthcare providers, leading to resistance.
- Walgreens implemented Aldriven automation in its prescription fulfillment process which led to job cuts and resistance from staff

## Strategies for Mitigation & The Value of Each Approach

- 1. **Data Privacy & Cybersecurity:** Require Multi-Factor Authentication (MFA) and Role-Based Access Control (RBAC) for AI systems handling sensitive data.
- 2. **Bias on AI models:** Regularly audit AI models to check for racial, gender, and socioeconomic disparities in claim approvals.
- 3. AI-Driven Drug Discovery and Clinical Insights: Partner with biotech firms, AI-driven pharma companies, and academic research institutions to share costs and accelerate AI drug research.



# Thank you for listening!

Do you have any questions?

**CVS**Health

